Drugs / Z0063
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03069963 | Feb → Apr 2017 | gastroesophageal reflux disease | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03065816 | Feb → May 2017 | gastroesophageal reflux disease | Sanofi | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Z0063 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03069963 ↗ |
| Route | Oral | “Route of administration: oral” NCT03065816 ↗ |